Sage Journals: Discover world-class research

Abstract

Background:

Insulin pen devices are currently being used by approximately half of insulin users worldwide. ClikSTAR® (sanofi-aventis) is a novel reusable insulin pen for injecting either long-acting insulin glargine or short-acting insulin glulisine. The objective of this study was to demonstrate that individuals with diabetes could use the ClikSTAR pen correctly.

Methods:

In this open-label, single-center study, people with diabetes delivered three 40 U insulin doses after receiving training from a diabetes specialist (group A, n = 256) or after self-training (group B, n = 47). Administration of a dose of 75–115% of the intended dose was considered successful. Adverse events (AEs) and product technical complaints (PTCs) were recorded.

Results:

In group A (68% females, 93% Hispanic ethnicity, 97% type 2 diabetes mellitus, mean ± standard deviation age 52 ± 11 years, diabetes duration 11 ± 7 years), half of the participants had prior experience in using insulin pen devices. All except one participant (99.6%) in group A successfully delivered three insulin doses. The lower one-tailed 95% confidence limit for the success rate (98.2%) was higher than the predefined target of 90%. Demographic/baseline characteristics were similar in group B, but 70% had not previously used an injection pen. Group B also showed success; 93.6% of participants successfully completed three dose deliveries. No AEs were reported, although one participant (0.4%) in group A reported one PTC during the training period that was due to a blocked needle.

Conclusions:

This study successfully validated the ClikSTAR pen for use by individuals with diabetes.

Keywords

design validation reusable insulin pen device type 2 diabetes mellitus

References

American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33 Suppl 1: S11–61.

Nathan

Buse

Davidson

Ferrannini

Holman

Sherwin

Zinman

, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32 (1): 193–203.

Korytkowski

Bell

Jacobsen

Suwannasari

, FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety Profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25 (11): 2836–48.

Selam

. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4 (3): 505–13.

Keith

Nicholson

Rogers

. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43 (1): 69–74.

Gnanalingham

Newland

Smith

. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79 (1): 59–62.

Clarke

Spollett

. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4 (2): 165–74.

Haak

Edelman

Walter

Lecointre

Spollett

. Comparison of usability and patient preference for the new disposable insulin device SoloSTAR versus Flexpen, Lilly disposable pen, and a prototype pen: An open-label study. Clin Ther. 2007;29 (4): 650–60.

Ignaut

Opincar

Clark

Palaisa

Lenox

. Engineering study comparing injection force and dose accuracy between two prefilled insulin injection pens. Curr Med Res Opin. 2009;25 (12): 2829–33.

10.

Ignaut

Opincar

Lenox

. FlexPen and KwikPen prefilled insulin devices: A laboratory evaluation of ergonomic and injection force characteristics. J Diabetes Sci Technol. 2008;2 (3): 533–7.

11.

Ignaut

Schwartz

Sarwat

Murphy

. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35 (5): 789–98.

12.

Pfützner

. FlexPen for the delivery of insulin: Accuracy, injection force and patient preference. Expert Rev Med Devices. 2009;6 (2): 115–23.

13.

Pfützner

Asakura

Sommavilla

Lee

. Insulin delivery with FlexPen: Dose accuracy, patient preference and adherence. Expert Opin Drug Deliv. 2008;5 (8): 915–25.

14.

IMS Health: IMS Midas™ July 2009, Insulin Sales Volume.

15.

Clarke

Dain

. Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Expert Opin Drug Deliv. 2006;3 (5): 677–83.

16.

Yki-Järvinen

Kauppinen-Mäkelin

Tiikkainen

Vähätalo

Virtamo

Nikkilä

Tulokas

Hulme

Hardy

McNulty

Hänninen

Levänen

Lahdenperä

Lehtonen

Ryysy

. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia. 2006;49 (3): 442–51.

17.

Lefkowitz

. Differing body colour of the SoloSTAR® pen enhances the ability of patients to distinguish between long- and short-acting insulin compared with the label colour used on other pen devices. Presented at: Diabetes Technology Meeting, San Francisco, CA, November 5–7, 2009.

Correct Use of a New Reusable Insulin Injection Pen by Patients with Diabetes: A Design Validation Study

Abstract

Background:

Methods:

Results:

Conclusions:

Keywords

References